Phase 2 RCT in 207 adults with antihistamine-refractory chronic spontaneous urticaria: barzolvolimab improved UAS7 at week 12 vs placebo at all doses (-6.60 to -13.41); hair colour change and urticaria were the commonest adverse events.
RCTn = 207
Metz et al. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria